Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A2

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 3, 2011, Pages 217-223

  Rizos, Christos V ^a   Liberopoulos, Evangelos N ^a   Tellis, Constantinos C ^b   Florentin, Matilda ^a   Elisaf, Moses S ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRBESARTAN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; ROSUVASTATIN; TELMISARTAN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; FRACTIONATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARTICLE SIZE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DRUG COMBINATIONS; ENZYME ACTIVATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PPAR GAMMA; PYRIMIDINES; SULFONAMIDES;

EID: 79957649043     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2010.0120     Document Type: Article

References (30)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
2. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982;23:97-104. (Pubitemid 12112617)
3. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006;99:1-14. (Pubitemid 43124966)
4. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-338.
5. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta 1994;1213:34-38. (Pubitemid 24204562)
6. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-2273. (Pubitemid 41692569)
7. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-1155.
8. Hatoum IJ, Hu FB, Nelson JJ, Rimm EB. Lipoproteinassociated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes 2010;59:1239-1243.
9. Anuurad E, Ozturk Z, Enkhmaa B, Pearson TA, Berglund L. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab 2010;95:2376-2383.
10. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-1544.
11. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Am J Cardiol 2003;92:152-160. (Pubitemid 36835963)
12. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-151.
13. Kostapanos MS,Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008;590:327-332.
14. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27: 2236-2243. (Pubitemid 350287255)
15. Rizos CV, Elisaf MS, Liberopoulos EN. Are the pleiotropic effects of telmisartan clinically relevant? Curr Pharm Des 2009;15:2815-2832.
16. Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, Liberopoulos EN. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study. Clin Ther 2010;32:492-505.
17. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002. (Pubitemid 38579904)
18. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, 3rd, Simons- Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10. (Pubitemid 32064838)
19. Apostolou F, Gazi IF, Kostoula A, Tellis CC, Tselepis AD, Elisaf M, Liberopoulos EN. Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res 2009;50:2532-2539.
20. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995;15:1764-1773.
21. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-462. (Pubitemid 36173203)
22. Festa A, D'Agostino R, Jr., Mykkanen L, Tracy RP, Hales CN, Howard BV, Haffner SM. LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22:1688-1693.
23. Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, Marz W. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: A double-blind, placebocontrolled study. Diabetes Care 2003;26:2588-2594. (Pubitemid 37052104)
24. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-1108. (Pubitemid 351721748)
25. Lautamaki R, Nuutila P, Airaksinen KE, Leino A, Hiekkanen H, Turiceanu M, Stewart M, Knuuti J, Ronnemaa T. The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud 2006;3:31-38.
26. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-253. (Pubitemid 24188766)
27. Basu A, Jensen MD, McCann F, Nandy D, Mukhopadhyay D, McConnell JP, Rizza RA. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr Pract 2007;13:147-152.
28. Sumita C, Maeda M, Fujio Y, Kim J, Fujitsu J, Kasayama S, Yamamoto I, Azuma J. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 2004;1673:115-121. (Pubitemid 38981764)
29. Rizos EC, Spyrou A, Liberopoulos EN, Papavasiliou EC, Saougos V, Tselepis AD, Elisaf M. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J 2007;1:22-26.
30. Tambaki AP, Rizos E, Tsimihodimos V, Tselepis AD, Elisaf M. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther 2004;9:91-95. (Pubitemid 39071594)